[ad_1]
Nail new russian coronavirus vaccine, prepared by the Federal Biomedical Agency of Russia (FMBA), protect from any viral mutation, press release vice-director of the establishment, Tatiana Ykovleva.
“The drug we are working on at the Russian FMBA also develops cellular immunity, i.e. focuses on conservative proteins; whatever mutation occurs, this vaccine will protect us from Covid-19“said Ykovleva in an interview with Izvestia.
On a related note, he shared his hope that the vaccine would be effective, although he added that data on its effectiveness will be published after clinical trials.
FMBA-designed Covid vaccine to be fourth to be developed in Russia, after Sputnik V of the Nikoli Gamaleya Epidemiology and Microbiology Center, EpiVacCorona of the Virology Center and Covivac of the Mijal Chumakov Vaccine Research and Development Center.
Vaccines vs. Variations: Will the world be successful in vaccinating herds?
Sputnik V was registered in Russia on August 11, 2020 and consists of two doses that are applied with an interval of 21 days. The first is based on human adenovirus type 26 and the second on recombinant human adenovirus type 5.
At the beginning of February, the British scientific journal The Lancet published the interim results of the third phase of the Russian vaccine clinical trial, which confirmed a safety and efficacy of 91.6%.
The vaccine is approved in more than 60 countries in America, Africa, Asia and Europe, including Argentina, Bolivia, Mexico and Venezuela. Sputnik News.
One by one, all payments made by the government to purchase vaccines
However, in countries like Argentina, the origin of the vaccine has been the subject of political debate and, at times, the debate surprises the uninformed.
.
[ad_2]
Source link